Content by PrECOG Cancer Research Group
|3 min read
New First-Line Lymphoma Treatment Well-Tolerated in Phase 2 Trial
Venetoclax administered with bendamustine+rituximab as the first therapy for mantle cell lymphoma led to 85 percent complete response ratePage 1 of 1
